S

Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581

Watchlist Manager
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Watchlist
Price: 10.64 CNY -1.39% Market Closed
Market Cap: 7B CNY
Have any thoughts about
Shandong Sinobioway Biomedicine Co Ltd?
Write Note

Shandong Sinobioway Biomedicine Co Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Sinobioway Biomedicine Co Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Long-Term Debt
ÂĄ320.4k
CAGR 3-Years
-77%
CAGR 5-Years
-79%
CAGR 10-Years
N/A
Fufeng Group Ltd
HKEX:546
Long-Term Debt
ÂĄ594.1m
CAGR 3-Years
4%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
G
GHW International
HKEX:9933
Long-Term Debt
ÂĄ241.6m
CAGR 3-Years
13%
CAGR 5-Years
126%
CAGR 10-Years
N/A
Ningxia Baofeng Energy Group Co Ltd
SSE:600989
Long-Term Debt
ÂĄ22.3B
CAGR 3-Years
74%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Zhejiang XinAn Chemical Industrial Group Co Ltd
SSE:600596
Long-Term Debt
ÂĄ2.3B
CAGR 3-Years
15%
CAGR 5-Years
33%
CAGR 10-Years
20%
A
Anhui Jinhe Industrial Co Ltd
SZSE:002597
Long-Term Debt
ÂĄ1.1B
CAGR 3-Years
-3%
CAGR 5-Years
18%
CAGR 10-Years
11%
No Stocks Found

Shandong Sinobioway Biomedicine Co Ltd
Glance View

Market Cap
7B CNY
Industry
Chemicals

In the bustling world of biotechnology, Shandong Sinobioway Biomedicine Co Ltd stands as a dynamic player, deeply embedded in the heart of China's burgeoning pharmaceutical and biotech sector. Founded with a vision to harness the power of biology for transformative impacts, the company has charted a remarkable journey rooted in innovation and robust research capabilities. Sinobioway primarily delves into the development and commercialization of biological products, focusing on vaccines, antibodies, and other biopharmaceuticals. By emphasizing advanced biotechnologies, the company creates life-enhancing solutions, addressing both common and complex health challenges. Its strategic approach involves a blend of cutting-edge research, partnerships with academic institutions, and collaborations with global pharmaceutical giants, paving the way for market-leading products. Revenue streams for Sinobioway are predominantly driven by its diverse product portfolio that caters to a wide array of medical needs. Through comprehensive R&D, they've effectively commandeered a niche within the preventive medicine sector, particularly with their vaccines, which are in high demand due to increasing health awareness and governmental health initiatives. Additionally, the company fortifies its financial foundation through licensing deals, tapping into global markets and establishing a significant presence internationally. By strategically optimizing production processes and deploying an efficient distribution network, Sinobioway ensures its biomedicine products reach various demographics, thereby anchoring its position in the bioscience industry while continually seeking growth and expansion opportunities beyond local confines.

Intrinsic Value
3.06 CNY
Overvaluation 71%
Intrinsic Value
Price
S

See Also

What is Shandong Sinobioway Biomedicine Co Ltd's Long-Term Debt?
Long-Term Debt
320.4k CNY

Based on the financial report for Jun 30, 2024, Shandong Sinobioway Biomedicine Co Ltd's Long-Term Debt amounts to 320.4k CNY.

What is Shandong Sinobioway Biomedicine Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-79%

Over the last year, the Long-Term Debt growth was -68%. The average annual Long-Term Debt growth rates for Shandong Sinobioway Biomedicine Co Ltd have been -77% over the past three years , -79% over the past five years .

Back to Top